I am generally aware that people can develop flares from FMT. I guess the question in this study is what exactly is meant by worsening, I generally suspect it means temporary worsening perhaps similar to a flare. But many people find improvement too!! Results may depend on the quality of the donors stool, stool is like an unstandardized drug formulation, you really never know what your going to get, but that's why the science must advance, it's the beginning stages.
Relevant: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2036.1987.tb00635.x
As a slde note, this article also discusses the topic of EN in a favourable way, if I remember correctly. It’s been some time since I read the whole paper.
If you introduce bacteria in mice with deficiencies relevant to crohn's disease you cause antigenic stimulation and you can create, or at least mimmick, crohn's disease in mice.
If on the other hand, you use a sterile environment, you can not, mice with genetic deficiencies relevant to crohn's, only get sick if you actively introduce bacteria.
Not only do they get sick if you introduce pathogenic bacteria, they also get sick if you introduce bacteria found in human stool that are harmless in mouse without the deficiencies, but cause inflammation in the KO mice with crohn's deficiencies.
If those irresponsible doctors experimenting with microbiota transplantation had read a singly study, they would have never tried microbiota transplanation where patients got worse instead of better.
You don't try your eperiment on humans when it causes disease in a mouse model, you don't introduce bacteria in people who have issues clearing bacteria. It is no wonder people with crohn's disease flare after micriobiota transplanation. How was this treatment even considered, let alone used. Thank god those experiments on crohn's disease patients seeemed to have all but stopped now.
If they want to try it in other diseases, that is their choice, but not in crohn's disease patients. They are patients, not test subjects.
Speaking of TNF inhibitors...
Even if they get the results they are hoping for, its a long uphill battle to unseat the giants selling their numerous temporary fix products.
The profit motive will encourage Qu biologics to develop their product as it is not replacing a more profitable product they have already.
However the pharmaceutical giants certainly are aware of the ramifications for their temporary fix medications if the new products are effective. They are not going to just sit by and let this tiny company take away their market share. They have all the power to crush whoever they want and they do it regularly.
I don’t know how it will occur, there are so many possibilities, but its no slam dunk even if its the best treatment in the world. Doesn’t work that way. It hasn’t for about a hundred years.
Dan
I had the most awful experience on LDN - its was a total disaster for me. I know it works for some people but I regret trying it more than I can put into words.There are very few GI’s aware of Low dose naltrexone either. Not because its any worse than any other treatment but because there are no drug reps promoting it. In this case its too cheap for any pharmaceutical company to even bother with. It would replace more profitable drugs.
Treatments you never hear about are not going to help many people.
I hope you are right, but the odds are not good.
Dan
The treatment (QBECO) is designed to activate an organ specific immune response. In this case by injecting elements of killed e'coli subcutaneously every second day. QBECO recruits activated innate immune cells into the intestinal mucosa, restoring innate immune competency, clearing dysbiosis and bacterial infection, removing the underlying trigger for the adaptive immune overreaction, resulting in disease resolution.Big pharma can use their power on regulatory institutions, political and judiciary system, media etc. to prevent the marketing of the Qu’s vaccine (assuming it will be a success). They may also buy the vaccine, and then it will be forgotten, or “the new data (or new analyses)” will show lack of effectiveness or safety concerns about the vaccine.
Qu biologics can also turn this into a lifelong treatment to maximise their profit. I don’t know how the treatment is designed and thought of now by them.
Big pharma can use their power on regulatory institutions, political and judiciary system, media etc. to prevent the marketing of the Qu’s vaccine (assuming it will be a success). They may also buy the vaccine, and then it will be forgotten, or “the new data (or new analyses)” will show lack of effectiveness or safety concerns about the vaccine.
Qu biologics can also turn this into a lifelong treatment to maximise their profit. I don’t know how the treatment is designed and thought of now by them.
Good post and many excellent points.It's pretty clear that big pharma is obsessed with big profits - to the point that it's fair to call them excessively greedy. But I think people are often too quick to assign to them an unwarranted level of evil and bad intentions. If the Qu vaccine or any other new product works great they won't want to crush it. They will want to own it. They will want to be the only company offering this exciting new product. They will want to reap the rewards of Qu's cleverness and hard work.
One often heard criticism is that big pharma deliberately suppresses cures in favor of chronic treatments to keep the money flowing long term. But the example in recent years of hepatitis C puts the lie to that notion. They had expensive, chronic treatments for Hep C going for years and years with interferon in combo with some anti-virals. It was expensive and didn't work very well. Then the new Hep C drugs were developed that are outright cures - miracle cures. It's been a revolution. No more chronic treatments. The long term money stream has stopped. So instead the pharma companies simply charge a fortune for the new Hep C cure drugs.
Big pharma LOVES new products. They spend many billions searching for new and exciting drugs. If Qu's technology works they'd be foolish to buy up Qu and then hide it under a bushel. It would be far better for them and much better aligned with their current business model buy it up, lock up its technology with as many patents as they can possibly obtain, and then charge an arm and a leg for it.
It's pretty clear that big pharma is obsessed with big profits - to the point that it's fair to call them excessively greedy. But I think people are often too quick to assign to them an unwarranted level of evil and bad intentions. If the Qu vaccine or any other new product works great they won't want to crush it. They will want to own it. They will want to be the only company offering this exciting new product. They will want to reap the rewards of Qu's cleverness and hard work.
One often heard criticism is that big pharma deliberately suppresses cures in favor of chronic treatments to keep the money flowing long term. But the example in recent years of hepatitis C puts the lie to that notion. They had expensive, chronic treatments for Hep C going for years and years with interferon in combo with the anti-viral drug ribavirin. It was expensive and didn't work very well. Then the new Hep C drugs were developed that are outright cures - miracle cures. Nobody sought to suppress these cures. It's been a revolution. No more chronic treatments. The long term money stream has stopped. So instead the pharma companies simply charge a fortune for the new Hep C cure drugs.
Big pharma LOVES new products. They spend many billions searching for new and exciting drugs. If Qu's technology works they'd be foolish to buy up Qu and then hide it under a bushel. It would be far better for them and much better aligned with their current business model buy it up, lock up its technology with as many patents as they can possibly obtain, and then charge an arm and a leg for it.
There is nothing inherently wrong or bad in a profit driven system. Its basically like gravity in that it is a force that is naturally there. It is a matter of having the incentives for profit put in the proper place and a truly free marketplace of ideas and products. One where small companies can innovate without the threat of being stepped on in the process. Where cheap treatments are allowed to exist without interference.
No one but big pharma can complete with big pharma. Only because they control virtually every aspect of treatment via their control of the FDA, media, scientific journals, etc. They answer to themselves for the most part.
It shows in our second rate health care system that politicians refer to as best in the world. Its not even in the top ten in the U.S. We have some good aspects of healthcare but overall it’s not nearly what it could or should be.
Ok. We are way off topic now but I truly hope that something better is coming because the current mainstream treatments are nothing to brag about. I am doing fine myself but there tens of thousands not as fortunate.
Dan
I truly hope that something better is coming because the current mainstream treatments are nothing to brag about.
What are people's thoughts about "natural" antimicrobial herbs to try and help keep bacteria under control.
I agree that claims and speculations about good and bad bacteria are bogus. Microbiota topic is highly complex with its interrelations with each other, the host, the environment, epigenetics etc. And the current knowledge about the topic is almost nil - compared to what needs to be known.
Segal AW, Studies on patients establish Crohn's disease as a manifestation of impaired innate immunity
Abstract
The fruitless search for the cause of Crohn's disease has been conducted for more than a century. Various theories, including autoimmunity, mycobacterial infection and aberrant response to food and other ingested materials, have been abandoned for lack of robust proof. This review will provide the evidence, obtained from patients with this condition, that the common predisposition to Crohn's is a failure of the acute inflammatory response to tissue damage. This acute inflammation normally attracts large numbers of neutrophil leucocytes which engulf and clear bacteria and autologous debris from the inflamed site. The underlying predisposition in Crohn's disease is unmasked by damage to the bowel mucosa, predominantly through infection, which allows faecal bowel contents access to the vulnerable tissues within. Consequent upon failure of the clearance of these infectious and antigenic intestinal contents, it becomes contained, leading to a chronic granulomatous inflammation, producing cytokine release, local tissue damage and systemic symptoms. Multiple molecular pathologies extending across the whole spectrum of the acute inflammatory and innate immune response lead to the common predisposition in which defective monocyte and macrophage function plays a central role. Family linkage and exome sequencing together with GWAS have identified some of the molecules involved, including receptors, molecules involved in vesicle trafficking, and effector cells. Current therapy is immunosuppressant, which controls the symptoms but accentuates the underlying problem, which can only logically be tackled by correcting the primary lesion/s by gene therapy or genome editing, or through the development of drugs that stimulate innate immunity.
...
TREATMENT
Treatment of CD poses a problem. It would be logical to correct the underlying pathogenesis by enhancing innate immunity, however, no such drugs are currently available.
Immunostimulation might exaggerate ongoing bowel inflammation. However, if developed, such treatments, could be useful to maintain patients in remission after they had been cleared of disease by surgical resection, or through the use of non-immunosuppressant therapies such as elemental diets(119), They might also be useful as a prophylactic measure in subjects like siblings of patients or members of families with multiply affected individuals at high risk of developing the disease.
Past attempts to stimulate immunity with Levamisole were unsuccessful(120) and GM-CSF was modestly effective but was never adopted as an FDA approved treatment(121).
An alternative approach that is likely to be applied in the near future, given that most of the defective genes are in myeloid cells in the bone marrow, would be transplantation of autologous bone marrow transfected with the normal gene or altered by genome editing, into conditioned recipients.
There is evidence that allogeneic bone marrow transplantation can cure CD(122) but risk of death or major side effects precludes its routine use except in children with severe monogenic disease. It was hoped that autologous haematopoetic stem cell transplantation into conditioned patients might “reset” the immune system without correcting the underlying genetic lesion, but a randomised trial did not result in a statistically significant improvement and was associated with significant toxicity(123).
Specific correction of the causal genetic lesions appears logical and is becoming increasingly feasible. Gene therapy using viral vectors to transfect haemopoietic stem cells with the wild-type gene now provides standard clinical practise for several primary immunodeficiency diseases and other conditions(124). This approach should be currently applicable to treat CD where the causal gene defect is readily identifiable, for example in subjects with homozygous truncating mutations in NOD2. In the near future, improvements in gene editing technologies should lead to a personalised medicine approach with the correction of the genetic architecture of individual patients as the contributions to their disease by individual variants in genes regulating innate immunity become better defined and easier to identify.
Great find. This article really seems to be on the right track.
Or they don’t event know about it??
While the cause of Crohn's disease is unknown, it is believed to be due to a combination of environmental, immune, and bacterial factors in genetically susceptible individuals.[6][7][8] It results in a chronic inflammatory disorder, in which the body's immune system attacks the gastrointestinal tract, possibly targeting microbial antigens.[7][9] While Crohn's is an immune-related disease, it does not appear to be an autoimmune disease(in that the immune system is not being triggered by the body itself).[10]The exact underlying immune problem is not clear; however, it may be an immunodeficiency state.[9][11][12]
References ([9][11][12]):
- Marks DJ, Rahman FZ, Sewell GW, Segal AW (February 2010). "Crohn's disease: an immune deficiency state". Clinical Reviews in Allergy & Immunology. 38 (1): 20–31. doi:10.1007/s12016-009-8133-2. PMC 4568313. PMID 19437144.
- Casanova JL, Abel L (August 2009). "Revisiting Crohn's disease as a primary immunodeficiency of macrophages". The Journal of Experimental Medicine. 206 (9): 1839–43. doi:10.1084/jem.20091683. PMC 2737171. PMID 19687225.
- Lalande JD, Behr MA (July 2010). "Mycobacteria in Crohn's disease: how innate immune deficiency may result in chronic inflammation". Expert Review of Clinical Immunology. 6 (4): 633–41. doi:10.1586/eci.10.29. PMID 20594136.
...
Cause
Risk factors
While the exact cause is unknown, Crohn's disease seems to be due to a combination of environmental factors and genetic predisposition.[46] Crohn's is the first genetically complex disease in which the relationship between genetic risk factors and the immune system is understood in considerable detail.[47] Each individual risk mutation makes a small contribution to the overall risk of Crohn's (approximately 1:200). The genetic data, and direct assessment of immunity, indicates a malfunction in the innate immune system.[48] In this view, the chronic inflammation of Crohn's is caused when the adaptive immune system tries to compensate for a deficient innate immune system.[49]
Crohn's disease Ulcerative colitis Smoking Higher risk for smokers Lower risk for smokers[44] Age Usual onset between
15 and 30 years[45]Peak incidence between
15 and 25 years
Genetics
NOD2 protein model with schematic diagram. Two N-terminal CARD domains (red) connected via helical linker (blue) with central NBD domain (green). At C-terminus LRR domain (cyan) is located. Additionally, some mutations which are associated with certain disease patterns in Crohn's disease are marked in red wire representation.[50]
Crohn's has a genetic component.[51] Because of this, siblings of known people with Crohn's are 30 times more likely to develop Crohn's than the general population.
The first mutation found to be associated with Crohn's was a frameshift in the NOD2 gene (also known as the CARD15 gene),[52] followed by the discovery of point mutations.[53] Over thirty genes have been associated with Crohn's; a biological function is known for most of them. For example, one association is with mutations in the XBP1 gene, which is involved in the unfolded protein response pathway of the endoplasmic reticulum.[54][55] The gene variants of NOD2/CARD15 seem to be related with small-bowel involvement.[56] Other well documented genes which increase the risk of developing Crohn disease are ATG16L1,[57] IL23R,[58] IRGM,[59] and SLC11A1.[60] There is considerable overlap between susceptibility loci for IBD and mycobacterial infections.[61]Recent genome-wide association studies have shown that Crohn's disease is genetically linked to coeliac disease.[62]
Crohn's has been linked to the gene LRRK2 with one variant potentially increasing the risk of developing the disease by 70%, while another lowers it by 25%. The gene is responsible for making a protein, which collects and eliminates waste product in cells, and is also associated with Parkinson's disease.[63]
Immune system
There was a prevailing view that Crohn's disease is a primary T cell autoimmune disorder, however, a newer theory hypothesizes that Crohn's results from an impaired innate immunity.[64] The later hypothesis describes impaired cytokine secretion by macrophages, which contributes to impaired innate immunity and leads to a sustained microbial-induced inflammatory response in the colon, where the bacterial load is high.[7][48] Another theory is that the inflammation of Crohn's was caused by an overactive Th1 and Th17 cytokine response.[65][66]
In 2007, the ATG16L1 gene has been implicated in Crohn's disease, which may induce autophagy and hinder the body's ability to attack invasive bacteria.[57] Another study has theorized that the human immune system traditionally evolved with the presence of parasites inside the body, and that the lack thereof due to modern hygiene standards has weakened the immune system. Test subjects were reintroduced to harmless parasites, with positive response.[67]
Microbes
It is hypothesised that maintenance of commensal microorganism growth in the GI tract is dysregulated, either as a result or cause of immune dysregulation.[68][69]
A number of studies have suggested a causal role for Mycobacterium avium subspecies paratuberculosis (MAP), which causes a similar disease, Johne's disease, in cattle.[70][71]
NOD2 is a gene involved in Crohn's genetic susceptibility. It is associated with macrophages' diminished ability to phagocytize MAP. This same gene may reduce innate and adaptive immunity in gastrointestinal tissue and impair the ability to resist infection by the MAP bacterium.[72] Macrophages that ingest the MAP bacterium are associated with high production of TNF-α.[73][74]
Other studies have linked specific strains of enteroadherent E. coli to the disease.[75] Adherent-invasive Escherichia coli (AIEC), are more common in people with CD,[76][77][75] have the ability to make strong biofilms compared to non-AIEC strains correlating with high adhesion and invasion indices[78][79] of neutrophils and the ability to block autophagy at the autolysosomal step, which allows for intracellular survival of the bacteria and induction of inflammation.[80] Inflammation drives the proliferation of AIEC and dysbiosis in the ileum, irrespective of genotype.[81] AIEC strains replicate extensively inside macrophages inducing the secretion of very large amounts of TNF-α.[82]
Mouse studies have suggested some symptoms of Crohn's disease, ulcerative colitis, and irritable bowel syndrome have the same underlying cause. Biopsy samples taken from the colons of all three patient groups were found to produce elevated levels of a serine protease.[83] Experimental introduction of the serine protease into mice has been found to produce widespread pain associated with irritable bowel syndrome, as well as colitis, which is associated with all three diseases.[84] Regional and temporal variations in those illnesses follow those associated with infection with the protozoan Blastocystis.[85]
The "cold-chain" hypothesis is that psychrotrophic bacteria such as Yersinia and Listeria species contribute to the disease. A statistical correlation was found between the advent of the use of refrigeration in the United States and various parts of Europe and the rise of the disease.[86][87][88]
There is an apparent connection between Crohn's disease, Mycobacterium, other pathogenic bacteria, and genetic markers.[89][90] In many individuals, genetic factors predispose individuals to Mycobacterium avium subsp.paratuberculosis infection. This bacterium then produces mannins, which protect both itself and various bacteria from phagocytosis, thereby causing a variety of secondary infections.[91]
Still, this relationship between specific types of bacteria and Crohn's disease remains unclear.[92][93]
There is a tentative association between Candida colonization and Crohn's disease.[94]
I guess many scientists and doctors don’t agree with this theory, otherwise they’d suggest different therapies, right?
This thread, the impaired immunity paper, and the Qu Biologics trials are making me wonder if there's any role for pyrotherapy (inducing a fever) in Crohn's treatment. Has that been tested?
When I say ''crohn's disease'', I too strictly mean ileal disease, with no or negligeable colon involvement. I know far more about the ileum and peyer's patches than I do about the colon.
Haven't been on a lot, saw tag late.
Peyer's patches are normal to begin with, it's just a feature of the small intestine, it is the inflammation of them that is a sign of an issue.
Peyer's patches are tissue with immune cells. They're only found in the small intestine, you can see them with the naked eye through an endoscope, they look like little domes. The little dome bump is caused by the immune cells, the follicle. They're right on the surface of the intestinal wall, covered by M cells. I posted pictures of inflamed peyer's patches before. Peyer is from the person who discovered them, patches is because they're spread out like a patch. They're like mini lymph nodes in a way. Most people learn about lymph nodes long before they hear about peyer's patches so it's common to compare them to a lymph node.
Peyer's patches are like sensors, they're like the guards of the small intestine checking if everyone who is present in the small intestine is allowed to be there. If peyer's patches is the police station of the small intestine, then M cells are the gate that opens and closes. M cells are right on the surface, they actually aren't covered with mucus, and the guards at the M cells call in thousands of particles and antigens in to check for questioning in the peyer's patch.
The peyer's patch is filled with lymphocytes and dendritic cells. The immune system consists of the innate immune system and adaptive immune system. Dendritic cells awaken the adaptive immune cells if something has gone wrong (such as a salmonella infection), it's the alarm bell that will awaken those lymphocytes (B and T cells). They're often called antigen presenting cells, APC, since they present antigen to immune cells from the adaptive immune system as evidence that something is going horribly wrong in the body and they need new recruits to help, they're the alarm bell. Not only that, since those peyer's patches are conected to the lymphatic system, it will start recruiting more and more immune cells until the threat is over.
Anyway, why the peyer's patches are interesting in crohn's disease. Is because they are specific to the small intestine, if inflamed they are the first signs with an endoscope of crohn's disease, they are most active during teen years (crohn's is most diagnosed during those years) and we know AIEC invades peyer's patches through those M cells (AIEC is associated with crohn's disease).
Our findings pose an important question: does the CD lesion selectively originate from the Peyer’s patch? In this regard, Lockhart-Mummery and Morson[2] reported in 1960 that the earliest microscopic change in CD was ulceration of the lymphoid follicles and Peyer’s patches in the terminal ileum. Since then, several investigators have reported that CD initially occurs as tiny aphthoid lesions at the sites of mucosal lymphoid follicles in the gastrointestinal tract[3-5]. Recently, Fujishima et al[3-5] investigated ultrastructurally the epithelium covering solitary lymphoid nodules using biopsy samples obtained from the colorectum during colonoscopy, and indicated that the red halo appearance of such epithelia seemed to precede visible aphthoid ulcers. They suggested that ulcerations in CD might originate from the follicle-associated epithelium (FAE), possibly related to its role as a portal entry for potentially pathogenic agents. These studies have led to the concept that CD could originate from GALT including Peyer’s patches and lymphoid follicles in the terminal ileum[3-8]. With this concept[3-7], one can explain the reason for the occurrence of the skip lesions and the frequent involvement of the terminal ileum in CD.
Antigen-related Cell Adhesion Molecule 6 (CEACM6), favour the colonization of terminal ileum by entero adherent-invasive Escherichia coli (AIEC).
If they read...
gastros often don't understand why these secondary symptoms present themselves.
natural/medicinal way to boost macrophage activity?
''medicinal'' is GM-CSF, Granulocyte-macrophage colony-stimulating factor, but it wasn't approved by the FDA for crohn's disease. It worked reasonably well in kids with CD, but not good enough in adults.
New insights provided by the results of genome-wide association scanning in Crohn's disease highlight autophagy, a cellular process implicated in the clearance of intracellular bacteria, as a key process in Crohn's disease pathogeneses. Sirolimus (rapamycin) is a drug used to upregulate autophagy in cell culture in the laboratory, and in clinical practice to prevent rejection following organ transplantation due to independent immunosuppressive action.
Use of sirolimus (rapamycin) to treat refractory Crohn's disease. - PubMed - NCBI
Mohamed Mutalib, Osvaldo Borrelli, Sarah Blackstock, Fevronia Kiparissi, Mamoun Elawad, Neil Shah, Keith Lindley, The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children, Journal of Crohn's and Colitis, Volume 8, Issue 12, 1 December 2014, Pages 1730–1734, https://doi.org/10.1016/j.crohns.2014.08.014
https://clinicaltrials.gov/ct2/show/NCT02675153
What would be an optimal level of vitamin D you think? I checked my levels this year and last year and they were around 35-40, so not low but not high...
These are currently recruiting phase 3 and phase 4 studies for Crohn’s, all around the world:
https://www.clinicaltrials.gov/ct2/...ndr=&type=&rslt=&phase=2&phase=3&Search=Apply
Three quarter of all lymphocytes are in mucosal tissue. The intestine is the main entry point of bacteria.
Considering crohn's disease is an innate immunodeficiency of macrophages, crohn's disease patients should not just be seen by a gastro, but by a gastro and an immunologist.
The reason I said that crohn's disease patients should also be followed by immunologists is because the innate immunodefficiency is why people with crohn's disease develop extraintestinal manifestations like aphthous ulcers, uveitis, secondary infections, why some have lymphopenia, etc.
Most (if not all) of the common extraintestinal manifestations are simply a consequence of innate immunodeficiency, that are also seen in other innate immunodeficiency diseases. People who specialize in innate immunodeficiency diseases such as immunologists, understand and can properly treat those manifestations, gastros often don't understand why these secondary symptoms present themselves.
Well, ''natural'' is keeping optimal levels of Vitamin D.
What about Rifaximin? Seems a good treatment option too.
Crohn's disease is an immunodeficiency state where the innate immune system (especially the macrophages in the intestine) are unable to clear luminal content that has entered the intestinal wall. The initial lack of secretion of inflammatory cells, causes a chronic response from the adaptive immune system, T cells are chronically being recruited by APC like dendritic cells.
What remicade (and all other anti-inflammatory medication used for CD) does is block that secondary immune response.
This leads to lowering of inflammation. But the problem is that lumen content (mostly from the fecal stream) that has entered the intestinal wall, is now not cleared at all, because medication is actively blocking the immune response.
Infliximab never used to be chronically administered in the past, it was used a single time to stop inflammation. If you chronically administer infliximab like they do now, you are just going to stimulate the underlying lesions over time.
''The Lancet, 2006 Feb
Department of Medicine, University College London
Defective acute inflammation in Crohn's disease: a clinical investigation.
INTERPRETATION:
In Crohn's disease, a constitutionally weak immune response predisposes to accumulation of intestinal contents that breach the mucosal barrier of the bowel wall, resulting in granuloma formation and chronic inflammation. Polymorphisms in CARD15 do not underlie this phenotype, but incapacitate the NOD2 pathway that can compensate for impairment of innate inflammation. Current treatment of secondary chronic inflammation might exaggerate the underlying lesion and promote chronic disease.''
Are you saying that Crohn’s is a state where the immune system is too weak to clear intestinal contents that have entered the lining of the intestines?
A secondary response by the immune system causes inflammation.
The body is producing the inflammation to try and clear the foreign particles within the lining of the intestines. Remicade puts down that inflammation. However, the original problem of intestinal contents within the lining of the intestines remains. the body’s response to clear the foreign particles is damped down by the medication hence over time the situation gets worse.
If that is correct, then after that I am totally confused. I cannot work out what exactly a fecal stream is. Is it the passage of food from throat to anus?
If so how can something like that possibly be diverted? There is only one way down.
And how does the foreign particles enter the lining of the intestines in the first place? Is this the leaky gut problem?
Is the particles themselves or bacteria that are somehow attached to the particles that are the problem?
Is the solution to strengthen the immune system while healing the gut lining?
The acute innate immune response is insufficient. There are deficiencies at the macrophage level, which leads to insufficient neutrophil response.
We know this because we can see in tests that response to heat killed E Coli in CD patients for example, is delayed. We also know this because the genetic mutations and genetic predispositions in CD tell us.
Right, the weak innate immune system keeps chronically activating the adaptive immune system to compensate. Activation of the adaptive (or secondary) response is primarily done through dendritic cells that will present antigen to T lymphocytes.
In crohn's disease, this activation of the adaptive response becomes chronic due to the constant failures at the macrophage level to clear pathogens.
right
right
Fecal stream is diverted in several different ways, you have surgical faecal stream diversion, and nonsurgical faecal diversion.
The first time people started to notice that fecal stream diversion lead to healing of the intestine, was during surgeries in the 90s. If you did a surgery on a CD patient, you are forced to do at least a partial fecal stream diversion. To doctor's surprise, the parts of the intestine that didn't any longer come into contact with fecal matter, healed.
That was surprising, this lead to the support of nonsurgical faecal diversion to actually treat active crohn's disease, nutrition administered through an IV, avoiding the whole intestine.
This also lead support to the use of EN. While EN isn't the same as faecal diversion, it most likely works in a similar way, EN limits the faecal stream due to its high bioavailability (EN contain medium chain triglycerides, sucrose and glucose, it optimizes the uptake of nutrients).
The intestine, especially the ileum, is permeable by design. Not just so it can uptake nutrients, but because it contains peyer's patches. M cells from peyer's patches are completely exposed to lumen content (by design).
Of course people with crohn's disease also simply have a breakdown of the intestinal barrier itself, which causes activation of immmune cells in the epithelium and lamina propria. It's not just peyer's patches being activated, but they are heavily involved in ileal CD.
It's a persistent antigen response, most likely bacterial, fungi, and particles that cause a response.
Strengthening the immune system would be nice and probably the ultimate goal. But there are very few options. You can correct the immuno defficiencies through genetic intervention (which has actually cured people with CD), but the goal should of course be a drug that corrects the macrophage defficiency without having to resort to gene modification.
Do you use antibiotics as needed or chronically?
As needed through an IV (they're not given orally, antibiotics should ideally always given through IV in CD patients, to spare their intestine, unless there it is a localised antibiotic of course, like rifaximin).
About antibiotics, could you elaborate on “sparing the intestines”? What happens to the intestines when you take the abx orally?
You just want to kill the bacteria that have entered the lamina propria, the wall of the intestine. Antibiotics are broad spectrum, you don't want to indescriminately kill all the bacteria in your intestine, that's why bacteriophage therapy is so interesting, it's specificity.
Fecal stream diversion and broad spectrum antibiotics like cipro and flagyl their action includes a large decrease in ''bacterial load''.
(note studies that show cipro and flagyl are far more effective in CD patients if taken orally, and not very effective IV)
(antibiotics related to secondary infections should be IV)
And how does the foreign particles enter the lining of the intestines in the first place? Is this the leaky gut problem?
Kiny, while I understand the theoretical basis of your stance on the current medications to treat Crohn’s, I am not sure if I understand your stance on what we as Crohn’s patients should do to manage this disease in practice.
If left untreated (i.e. not taking immunosuppressants chronically), Crohn’s would kill many of us. EN simply wouldn’t work for many Crohn’s patients, antibiotics are not effective for the long term. I understand why you say immunosuppressants are actually making Crohn’s even more problematic and more chronic.
We share the same opinions on where the research and development on treatment should focus, but that is mostly beyond our control (it is even beyond the control of researchers for the most part).
What should Crohn’s patients do, now, to manage their Crohn’s? Could you elaborate your thoughts on this by addressing these problems?
I argued that micriobiota transplantation would fail and make crohn's disease worse because you are introducing a fecal stream.
Good post and I agree. Most of us don't have any choice.I should clarify that, by “immunosuppressants”, I meant thiopurines, mtx, and biologics all together. It’s well known that the rate of loss of response to biologics is substantial. There have been proposed mechanisms for that, as you well know.
As far as I know, loss of response rates are a lot less (at the very least least it takes longer) for thiopurines in the management of Crohn’s, compared to biologics. There are many patients who have been in remission for decades by using thiopurines (or combination therapy) for their Crohn’s.
I agree and support your views on the need for questioning by all sides of this problem. I certainly acknowledge the problem and think everyone should do so. There’s been an urgent need for change - morally, economically, socially, theoretically-scientifically, politically, medically etc. for a long time, but the circumstances of our lives make us need to be realistic and take immediate action for our lives.
I am saying that, taking the immunosuppressants chronically has been the only option for most of us; for the other option is painful death from CD. We need to use whatever we can use right now. Do the immunosuppressants make the Crohn’s more problematic and chronic because of CD’s aetiopathogenesis? Maybe they do. Do most Crohn’s patients have an alternative? I don’t think they do. Even if all of us lived a mostly stress-free life with a very restricted diet (to prevent dietary causes of the worsening of CD) with good supplements and natural treatment methods etc. most of us would still require the addition of immunosuppressants as maintenance drugs. That’s because of the aggressive, stubborn and fatal nature of CD.
I agree with you about their side effects, their lack of success etc. but most of the CD patients still need to take the current drugs regularly.
How do these metallic particles enter the body
Is interaction with inorganic particles as important as interaction with bacteria and fungi...probably not, but there has been little research about this.
another case of failed microbiota transplantation in crohn's disease
december 2018
https://www.ncbi.nlm.nih.gov/pubmed/30643841
Case Report
A 35-year old man with a history of refractory ileocolonic Crohn’s disease with primary sclerosing cholangitis and recurrent CDI presented with watery diarrhea and abdominal pain. His medical history included refractory Crohn’s disease, first diagnosed at age 28, requiring multiple diverting ileostomies complicated by disease flare upon ileostomy takedown and non-response to multiple therapies, including thiopurines, methotrexate, infliximab, adalimumab, and vedolizumab. Despite counseling, the patient was not amenable to colectomy throughout his disease course. His disease course had been complicated by at least 7 episodes of CDI with positive C. difficile polymerase chain reaction (PCR) tests over the past 7 years corresponding to worsening of clinical symptoms, ultimately requiring long courses of suppressive antibiotic therapy with vancomycin and consideration for FMT in the past. He had negative C. difficile PCR studies between episodes.
Four months prior to this presentation, the patient was on ustekinumab maintenance therapy every 8 weeks with colonoscopy demonstrating mucosal healing and no histological evidence of active disease. An ileostomy takedown was performed at this time (Figure 1). Subsequent colonoscopy 2 months after takedown revealed mild colonic recurrence with few scattered aphthous ulcers noted in the sigmoid and descending colon; biopsies showed only mild histologic activity in the rectum. During this month, he also had an episode of
CDI (positive C. difficile PCR) that was subsequently treated with oral vancomycin.
Two months later, the patient had mild tenderness in the lower abdomen. He was afebrile with elevated inflammatory markers (C-reactive protein 2.2 mg/dL; erythrocyte sedimentation rate 35 mm/hr), and C. difficile PCR and stool bacterial pathogens studies were negative. With the intention to prevent future CDI recurrences after his recent episode and history of recurrent 7 prior episodes, FMT was performed via colonoscopy, which revealed mild pancolitis (Figure 2). He received ustekinumab the night following the FMT, which was four weeks after his previous dose, due to evidence of recurrent disease despite standard ustekinumab dosing.
Two days later, the patient was readmitted with fever, abdominal pain, and frequent bloody stools. C-reactive protein and erythrocyte sedimentation rate were elevated to 12.7 mg/dL and 58 mm/hr, respectively. Stool studies were negative for infection. Sigmoidoscopy 1 week after FMT demonstrated punched-out ulcerations in the sigmoid and descending colon (Figure 3). Biopsies for cytomegalovirus were negative. Albumin decreased from 4.0 g/dL on presentation to 2.1 g/dL. Intravenous solumedrol was given for 5 days with initial improvement, but due to worsening symptoms and continued C-reactive protein elevation upon transition to oral steroids, the patient requested diverting ileostomy for colonic healing while continuing on ustekinumab therapy. At follow-up 2 weeks later, he reported feeling well with no abdominal pain or fevers with healthy weight gain, and he was weaned off steroids. He has not experienced further CDI relapse and is currently continuing ustekinumab maintenance therapy every 4 weeks to maintain remission after ileostomy takedown.
Giving people with Crohn’s FMT is akin to putting fuel on fire. Especially when you take into consideration the facts that bacterial load is the most important cause of inflammation; also the innate immunodeficiency, the chronic use of immunosuppressants, the intestinal permeability problem etc. in Crohn’s patients.
If those irresponsible doctors experimenting with microbiota transplantation had read a singly study, they would have never tried microbiota transplanation where patients got worse instead of better.
The uncontrollable flares you see in crohn's disease patients after a fecal microbiota transplantation seem to happen 1 or 2 days after the transplantation. Which is exactly the time the adaptive immune system requires to mount a full response.
The FMT studies to treat crohn's disease has got to be some of the most ridiculous studies I have ever read.
Although this is a close second https://www.ncbi.nlm.nih.gov/pubmed/27215921
Adding stool full of bacteria didn't work.
Adding worms didn't work.
Maybe these same doctors will try treating their patients with salmonella, just to see what happens.
The immune system:
—
—
—
https://m.youtube.com/watch?v=CeVtPDjJBPU
https://en.m.wikipedia.org/wiki/Immune_system
Good post and I agree. Most of us don't have any choice.
The thing that I find most frustrating is that there is hope on the horizon - Qu BIologics being a prime example. In some ways, I am grateful for the biologics as I would be without a colon without them. On the other hand in say 5-10 years I believe we will be in a much better position in terms of the range, quality and side effect profile of available treatments.
I guess that's just the nature of how treatment develops - things improve incrementally. People who were diagnosed 20 years ago didn't have anywhere near the options we have now, but the same will be true we look back at this time in the future.